Empagliflozin/Linagliptin: A Review in Type 2 Diabetes

Drugs

Volumn 75, Issue 13, 2015, Pages 1547-1557

  Kim, Esther S ^a   Deeks, Emma D ^a  

^a Springer Mairangi Bay 0754 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; LINAGLIPTIN; METFORMIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE PANCREATITIS; ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DIARRHEA; DIET THERAPY; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TOLERABILITY; DYSLIPIDEMIA; ERYTHRODERMA; EXERCISE; GASTROENTERITIS; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK ASSESSMENT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION; ADULT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; PATHOPHYSIOLOGY;

ADULT; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84941188677     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0457-z     Document Type: Article

References (58)

1. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. 2014. http://www.cdc.gov. Accessed 30 Jul 2015.
2. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-24.
3. Tran L, Zielinski A, Roach AH, et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015;49(5):540-56.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care. 2015;38(1):140-9.
5. American Diabetes Association. Standards of medical care in diabetes: 2015. Diabetes Care. 2015;38(Suppl. 1):S1-93.
6. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-13.
7. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38(3):373-5.
8. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59.
9. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441-67.
10. ® (empagliflozin and linagliptin) tablets: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Aug 2015.
11. Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(15):1769-84.
12. McKeage K. Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(16):1927-46.
13. Chao EC, Henry RR. SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-9.
14. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
15. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175-82.
16. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83-90.
17. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. CPDD. 2013;2(2):152-61.
18. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213-9.
19. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331-45.
20. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613-21.
21. Kanada S, Koiwai K, Taniguchi A, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(6):613-7.
22. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
23. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3(1):10.
24. Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-94.
25. Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542-50.
26. Ring A, Brand T, Macha S, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol. 2013;12:70.
27. Ring A, Port A, Graefe-Mody EU, et al. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol. 2011;72(1):39-50.
28. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35(1):A33-42.
29. ® (linagliptin) tablets: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Aug 2015.
30. Graefe-Mody U, Giessmann T, Ring A, et al. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011;33(8):1096-103.
31. Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(11):873-9.
32. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667-78.
33. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2014;16(2):118-23.
34. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74(1):75-85.
35. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213-25.
36. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-93.
37. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394-402.
38. Barnett AH, DeFronzo R, Lewin A, et al. Consistent weight changes irrespective of baseline HbA1c with the combination of empagliflozin/linagliptin (EMPA/LINA) in subjects with type 2 diabetes (T2DM) [abstract no. 2594-PO]. In: 75th Scientific Sessions of the American Diabetes Association; 2015.
39. Patel S, DeFronzo R, Lewin A, et al. Safety and tolerability of combinations of empagliflozin/linagliptin (EMPA/LINA) for 52 weeks in subjects with type 2 diabetes (T2DM) [abstract no. 1259-P plus poster]. In: 75th Scientific Sessions of the American Diabetes Association; 2015.
40. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453-67.
41. US FDA. Invokana™ (canagliflozin) tablets: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Aug 2015.
42. US FDA. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. http://www.fda.gov/drugs/drugsafety. Accessed 30 Jul 2015.
43. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015. doi: 10.1210/jc.2015-1884.
44. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med. 2011;124(1 Suppl):S19-34.
45. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29(1):1-13.
46. Bell DSH. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15(4):291-300.
47. Hauber AB, Han S, Yang J-C, et al. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence. 2013;7:937-49.
48. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-88.
49. Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther. 2014;36(12):2072-9.
50. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76.
51. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42.
52. Lehrke M, Marx N, Patel S, et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther. 2014;36(8):1130-46.
53. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. 2015. http://www.ema.europa.eu/ema/. Accessed 30 Jul 2015.
54. Medicines and Healthcare products Regulatory Agency. Drug safety update: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis. 2015. https://www.gov.uk/drug-safety-update. Accessed 30 Jul 2015.
55. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015. doi: 10.2337/dc15-0843.
56. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1-87.
57. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438-47.
58. Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(5):410-7.